FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFIC	IAL OWNERS	HIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* WILLIAMS DOUGLAS E						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]									(Ch	eck all appli Direct	nship of Reportin applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specify	
	(F N IDEC INC NEY STRE	Z	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/01/2015										helow)	below)		below) & Development	
(Street) CAMBR (City)	IDGE M	IA (02142 (Zip)		4. l	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Appl Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person									on					
		Tab	le I - No	n-Deriv	/ative	Sec	uriti	ies Ac	quir	red,	Dis	posed o	of, or	Ben	eficial	ly Owne	t			
D. 11.00 01 00000111, (11.0011 0)			2. Transa Date (Month/I	Ex Day/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			(A) or 3, 4 and	Benefic	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										ode	v	Amount	(A (D	() or ()	Price	Transac (Instr. 3	tion(s)			(111311. 4)
Common	Stock			02/01	./2015				N	М		5,157		A	\$0	13,133			D	
Common	Stock			02/01	/2015				1	F		2,059		D	\$389.1	16 11	,074	D		
		Т	able II -									osed of converti				Owned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	ate Execution	Date, Transa Code (6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisabl		Expiration Date	Title		Amount or Number of Shares					
Restricted	\$0 ⁽¹⁾	02/01/2015			M			5,157		(2)		02/01/2015	Comn	non	5.157	\$0	0		D	

Explanation of Responses:

/s/ Matthew S. Gilman,

Attorney-in-fact for Douglas E. 02/02/2015

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} There is no conversion or exercise price for this stock unit.

^{2.} The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).